Cullinan Therapeutics News

Cullinan Therapeutics (CGEM.US) was first covered by Stifel, giving it a buy rating, with a target price of $40.00.

Zhitong FinanceMay 1 17:50

Cullinan Therapeutics Analyst Ratings

BenzingaMay 1 17:47

Stifel Initiates Coverage On Cullinan Therapeutics With Buy Rating, Announces Price Target of $40

BenzingaMay 1 17:49

JonesTrading: Maintaining the Cullinan Therapeutics (CGEM.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $22.00 to $26.00.

Zhitong FinanceApr 18 19:01

Cullinan Oncology Analyst Ratings

BenzingaApr 17 23:17

HC Wainwright & Co. : Maintain the Cullinan Oncology (CGEM.US) rating, adjust from buy to buy rating, and adjust the target price from $34.00 to $29.00.

Zhitong FinanceApr 17 01:00

Cullinan Oncology Analyst Ratings

BenzingaApr 17 00:51

HC Wainwright & Co. Maintains Buy on Cullinan Oncology, Lowers Price Target to $29

BenzingaApr 17 00:54

Cullinan Oncology Analyst Ratings

BenzingaApr 15 20:10

Cullinan Oncology Analyst Ratings

BenzingaMar 15 00:42

HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Maintains $34 Price Target

BenzingaMar 15 00:44

Cullinan Oncology Analyst Ratings

BenzingaFeb 15 21:49

Wedbush Starts Cullinan Oncology With Outperform Rating, $30 Price Target

MT NewswiresFeb 15 19:21

Cullinan Oncology Analyst Ratings

BenzingaOct 6, 2023 17:49

HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Lowers Price Target to $34

BenzingaAug 12, 2023 01:10

Cullinan Oncology Analyst Ratings

BenzingaAug 12, 2023 01:09

Cullinan Oncology Analyst Ratings

BenzingaAug 9, 2023 22:28

Analyst Ratings for Cullinan Oncology

BenzingaJul 7, 2023 20:04

HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Maintains $49 Price Target

BenzingaJul 7, 2023 18:05

HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Maintains $49 Price Target

BenzingaJun 5, 2023 18:30